These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 16973358)
1. Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents. Humphries PS; Bailey S; Almaden JV; Barnum SJ; Carlson TJ; Christie LC; Do QQ; Fraser JD; Hess M; Kellum J; Kim YH; McClellan GA; Ogilvie KM; Simmons BH; Skalitzky D; Sun S; Wilhite D; Zehnder LR Bioorg Med Chem Lett; 2006 Dec; 16(23):6120-3. PubMed ID: 16973358 [TBL] [Abstract][Full Text] [Related]
2. Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents. Humphries PS; Almaden JV; Barnum SJ; Carlson TJ; Do QQ; Fraser JD; Hess M; Kim YH; Ogilvie KM; Sun S Bioorg Med Chem Lett; 2006 Dec; 16(23):6116-9. PubMed ID: 16979341 [TBL] [Abstract][Full Text] [Related]
3. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists. Oon Han H; Kim SH; Kim KH; Hur GC; Joo Yim H; Chung HK; Ho Woo S; Dong Koo K; Lee CS; Sung Koh J; Kim GT Bioorg Med Chem Lett; 2007 Feb; 17(4):937-41. PubMed ID: 17157019 [TBL] [Abstract][Full Text] [Related]
5. Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I. Devasthale PV; Chen S; Jeon Y; Qu F; Ryono DE; Wang W; Zhang H; Cheng L; Farrelly D; Golla R; Grover G; Ma Z; Moore L; Seethala R; Sun W; Doweyko AM; Chandrasena G; Sleph P; Hariharan N; Cheng PT Bioorg Med Chem Lett; 2007 Apr; 17(8):2312-6. PubMed ID: 17292606 [TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia. Liu K; Xu L; Berger JP; Macnaul KL; Zhou G; Doebber TW; Forrest MJ; Moller DE; Jones AB J Med Chem; 2005 Apr; 48(7):2262-5. PubMed ID: 15801817 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. Kim E; Park CS; Han T; Bae MH; Chong W; Lee CH; Shin YA; Ahn BN; Kim MK; Shin CY; Son MH; Kim JK; Moon HS; Shim HJ; Kim EJ; Kim SH; Lim JI; Lee CH Bioorg Med Chem Lett; 2008 Sep; 18(18):4993-6. PubMed ID: 18771917 [TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists. Pingali H; Jain M; Shah S; Makadia P; Zaware P; Goel A; Patel M; Giri S; Patel H; Patel P Bioorg Med Chem; 2008 Aug; 16(15):7117-27. PubMed ID: 18625559 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. Suh YG; Kim NJ; Koo BW; Lee KO; Moon SH; Shin DH; Jung JW; Paek SM; Chang DJ; Li F; Kang HJ; Le TV; Chae YN; Shin CY; Kim MK; Lim JI; Ryu JS; Park HJ J Med Chem; 2008 Oct; 51(20):6318-33. PubMed ID: 18826205 [TBL] [Abstract][Full Text] [Related]
10. Dual PPAR-alpha and -gamma activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential. Madhavan GR; Chakrabarti R; Reddy KA; Rajesh BM; Balraju V; Rao PB; Rajagopalan R; Iqbal J Bioorg Med Chem; 2006 Jan; 14(2):584-91. PubMed ID: 16198573 [TBL] [Abstract][Full Text] [Related]
11. Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. Zaware P; Shah SR; Pingali H; Makadia P; Thube B; Pola S; Patel D; Priyadarshini P; Suthar D; Shah M; Jamili J; Sairam KV; Giri S; Patel L; Patel H; Sudani H; Patel H; Jain M; Patel P; Bahekar R Bioorg Med Chem Lett; 2011 Jan; 21(2):628-32. PubMed ID: 21195611 [TBL] [Abstract][Full Text] [Related]
12. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists. Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897 [TBL] [Abstract][Full Text] [Related]
13. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy. Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610 [TBL] [Abstract][Full Text] [Related]
14. Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists. Makadia P; Shah SR; Pingali H; Zaware P; Patel D; Pola S; Thube B; Priyadarshini P; Suthar D; Shah M; Giri S; Trivedi C; Jain M; Patel P; Bahekar R Bioorg Med Chem; 2011 Jan; 19(2):771-82. PubMed ID: 21215640 [TBL] [Abstract][Full Text] [Related]
16. Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents. Raval P; Jain M; Goswami A; Basu S; Gite A; Godha A; Pingali H; Raval S; Giri S; Suthar D; Shah M; Patel P Bioorg Med Chem Lett; 2011 May; 21(10):3103-9. PubMed ID: 21450468 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists. Zhang H; Ryono DE; Devasthale P; Wang W; O'Malley K; Farrelly D; Gu L; Harrity T; Cap M; Chu C; Locke K; Zhang L; Lippy J; Kunselman L; Morgan N; Flynn N; Moore L; Hosagrahara V; Zhang L; Kadiyala P; Xu C; Doweyko AM; Bell A; Chang C; Muckelbauer J; Zahler R; Hariharan N; Cheng PT Bioorg Med Chem Lett; 2009 Mar; 19(5):1451-6. PubMed ID: 19201606 [TBL] [Abstract][Full Text] [Related]
18. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists. Grether U; Bénardeau A; Benz J; Binggeli A; Blum D; Hilpert H; Kuhn B; Märki HP; Meyer M; Mohr P; Püntener K; Raab S; Ruf A; Schlatter D ChemMedChem; 2009 Jun; 4(6):951-6. PubMed ID: 19326383 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities. da Costa Leite LF; Veras Mourão RH; de Lima Mdo C; Galdino SL; Hernandes MZ; de Assis Rocha Neves F; Vidal S; Barbe J; da Rocha Pitta I Eur J Med Chem; 2007 Oct; 42(10):1263-71. PubMed ID: 17448573 [TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity. Shi GQ; Dropinski JF; McKeever BM; Xu S; Becker JW; Berger JP; MacNaul KL; Elbrecht A; Zhou G; Doebber TW; Wang P; Chao YS; Forrest M; Heck JV; Moller DE; Jones AB J Med Chem; 2005 Jun; 48(13):4457-68. PubMed ID: 15974597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]